Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-Ascending Dose Study of LY3298176 in Japanese Patients With Type 2 Diabetes Mellitus
jRCT2080223709Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing LY3298176 with Placebo (2 arms). Primary endpoints: Safety and tolerability of LY3298176, Pharmacokinetics of LY3298176 and 1 more. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080223709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223709.